Kiniksa Pharmaceuticals International, PlcNASDAQ: KNSA

Kiniksa Announces Positive Data from Phase 3 Trial of Rilonacept in Recurrent Pericarditis (RHAPSODY)

· Issued by Kiniksa Pharmaceuticals International, Plc
Watch Kiniksa Pharmaceuticals International explain itKiniksa Pharmaceuticals International, plc (KNSA) Q2 2026 Earnings Call · Replay · Jul 28
  • Primary and all major secondary efficacy endpoints were highly statistically significant 
  • Rilonacept treatment resulted in a 96% reduction in risk of recurrent pericarditis events (primary efficacy endpoint: Hazard Ratio = 0.04, p